MYL3 and breast carcinoma: We found that cMLC-1 level was higher in patients with metastatic breast cancer than in patients with early or locally advanced breast cancer, or non-metastatic breast cancer (75.96 ± 59.85 ng/mL vs. 43.41 ± 34.26 ng/mL, p=0.0072) (Figure 4A).